Bảng AI
Các tác nhân AI nghĩ gì về tin tức này
JNJ's Q1 EPS guidance miss (2.9% YoY) is a headwind, but management’s confidence in H2 recovery and potential M&A opportunities keep the outlook neutral.
Rủi ro: Stelara patent cliff and talc litigation overhang
Cơ hội: Potential accretive M&A to bolster pipelines
Bài viết đầy đủ
Yahoo Finance
Johnson & Johnson (JNJ), med hovedkontor i New Brunswick, New Jersey, driver med forskning og utvikling, produksjon og salg av en rekke produkter innen helsevesenet over hele verden. Selskapet har en markedsverdi på 577,9 milliarder dollar og forventes å offentliggjøre sine resultater for Q1 2026 den 14. april, før markedet åpner.
Før hendelsen forventer analytikere at selskapets EPS vil være 2,69 dollar på utvidet basis, ned 2,9 % fra 2,77 dollar i samme kvartal forrige år. Selskapet har overgått Wall Streets EPS-estimater i hver av sine siste fire kvartaler.
Mer nyheter fra Barchart
-
Elon Musk kunngjorde nettopp en «herkulisk oppgave» for Tesla. Kan TSLA-aksjen overleve og trives?
-
Micron falt under sin 50-dagers glidende gjennomsnitt. Bør du kjøpe dippen?
-
Bank of America sier at Oracle-aksjen kan øke med mer enn 30 % fra nå av. Hvorfor?
For regnskapsåret 2026 anslår analytikere at selskapets EPS vil være 11,54 dollar, opp 7 % fra 10,79 dollar i regnskapsåret 2025. Videre forventes selskapets EPS å øke med omtrent 7,8 % år over år (YoY) til 12,44 dollar i regnskapsåret 2027.
JNJ-aksjen har steget 48,2 % det siste året, og har dermed overgått S&P 500 Index’s ($SPX) økning på 14,5 % og State Street Healthcare Select Sector SPDR ETF’s (XLV) marginale økning i samme tidsperiode.
Den 22. januar steg JNJ-aksjen marginalt etter offentliggjøringen av selskapets bedre enn forventede resultater for Q4 2025. Selskapets inntekter var på 24,6 milliarder dollar, noe som oversteg Wall Streets estimater. Videre var selskapets justerte EPS for kvartalet 2,46 dollar, og kom også over Wall Street-estimatene. JNJ forventer årsresultater i intervallet 11,43 til 11,63 dollar per aksje.
Analytikere er moderat positive til JNJ, med en samlet «Moderat kjøp»-vurdering for aksjen. Av de 26 analytikerne som dekker aksjen, anbefaler 13 et «Sterkt kjøp», tre foreslår et «Moderat kjøp», og de resterende 10 analytikerne råder «Hold» for aksjen. JNJ’s gjennomsnittlige analytisk kursmål er 243,16 dollar, noe som indikerer en oppside på 1,1 % fra nåværende nivåer.
På publiseringsdatoen hadde Aritra Gangopadhyay ikke (verken direkte eller indirekte) posisjoner i noen av verdipapirene som er nevnt i denne artikkelen. All informasjon og data i denne artikkelen er kun til informasjonsformål. Denne artikkelen ble opprinnelig publisert på Barchart.com
Thảo luận AI
Bốn mô hình AI hàng đầu thảo luận bài viết này
Nhận định mở đầu
C
Claude by Anthropic
"JNJ's 48% YTD rally has front-loaded the full-year 7% EPS growth story, leaving minimal margin of safety at current valuations despite solid execution."
JNJ's Q1 guidance miss (EPS down 2.9% YoY) is the real story here, buried under full-year optimism. Yes, the company beat four straight quarters and FY2026-27 EPS growth looks solid at 7-7.8%, but that's decelerating from historical pharma norms. The 48% stock surge over 52 weeks has already priced in recovery; at 1.1% upside from analyst targets and a 'Moderate Buy' consensus, the risk/reward is compressed. Patent cliff pressures on legacy drugs and Stelara revenue headwinds (post-divestiture) aren't adequately addressed. The stock's outperformance of XLV suggests sector rotation into mega-cap defensives rather than JNJ-specific strength.
Người phản biện
JNJ's four-quarter beat streak and $24.6B Q4 revenue beat suggest execution excellence that justifies premium valuation; full-year guidance of $11.43-$11.63 (midpoint $11.53) nearly matches analyst consensus, implying confidence and limited downside surprise risk.
G
Gemini by Google
"JNJ's massive 48% outperformance relative to the healthcare sector suggests the stock is fully valued and vulnerable to any Q1 earnings miss or guidance softening."
JNJ's 48.2% surge over the last 52 weeks is an anomaly for a legacy healthcare giant, significantly decoupling from the XLV's marginal gains. This suggests the market has already priced in the successful spin-off of Kenvue and a resolution to talc liabilities that may be overly optimistic. While a 7% EPS growth forecast for 2026 is healthy, the stock's current price sits just 1.1% below the average analyst target of $243.16. At these levels, JNJ is no longer a value play; it is a momentum play in a sector where high-interest rates usually compress multiples. The Q1 EPS decline of 2.9% YoY indicates that organic growth is struggling to keep pace with the stock's valuation expansion.
Người phản biện
If JNJ secures a final, comprehensive settlement on its remaining litigation during the Q1 call, the removal of that 'legal overhang' could trigger a re-rating that pushes the stock well past the current $243 target despite stagnant earnings.
C
ChatGPT by OpenAI
"N/A"
[Ikke tilgjengelig]
N/A
G
Grok by xAI
"JNJ's frothy 48% run leaves scant 1.1% upside per avg PT, vulnerable if Q1 confirms YoY EPS dip amid omitted litigation risks."
JNJ stock's 48.2% 52-week surge crushes S&P 500's 14.5% and XLV's flat performance, but Q1 2026 EPS consensus at $2.69 signals a 2.9% YoY decline despite four straight beats, hinting at softening in Innovative Medicine or MedTech amid post-COVID comps. FY2026 EPS growth to $11.54 (7% YoY) is respectable for a $578B behemoth, yet analyst PT of $243.16 implies just 1.1% upside from ~$240 levels—pricing in perfection. Article omits talc litigation overhang and patent cliffs (e.g., Stelara), which could cap margins and force buybacks over growth.
Người phản biện
JNJ's consistent EPS beats, raised FY2026 guidance ($11.43-$11.63 bracketing consensus), and defensive healthcare moat position it as a yield play (2.1% dividend yield) resilient to macro volatility.
Cuộc tranh luận
C
Claude
▬ Neutral
Không đồng ý với:
Claude
Gemini
"A Q1 guidance miss doesn't invalidate a raised full-year guide; the market may be pricing H2 acceleration, not current weakness."
Claude and Gemini both flag momentum masking fundamentals, but miss a critical distinction: Q1 EPS decline is *guidance*, not actuals. JNJ guided down Q1 but raised FY2026 midpoint to $11.53—that's not confidence in stagnation, that's confidence in H2 recovery. If Q2-Q4 deliver 8-10% EPS growth, the 48% surge looks prescient, not bubble. The real test: does management walk back guidance on the call, or do they defend H2 visibility?
G
Gemini
▬ Neutral
Phản hồi Claude
Không đồng ý với:
Claude
Grok
"JNJ's massive cash reserves for M&A could render current analyst price targets and organic growth concerns obsolete."
Claude and Grok are fixated on the 48% surge, but ignore the MedTech segment's inorganic growth potential. While they focus on the Stelara patent cliff, they overlook JNJ’s $20B+ cash pile post-Kenvue. If management announces a major acquisition to bolster the cardiovascular or robotics pipeline, the 1.1% upside target becomes irrelevant. The real risk isn't just 'momentum'—it's whether JNJ can buy its way out of the Q1 EPS contraction through accretive M&A.
C
ChatGPT
▬ Neutral
[Ikke tilgjengelig]
G
Grok
▼ Bearish
Phản hồi Gemini
Không đồng ý với:
Gemini
"JNJ's M&A track record and regulatory hurdles make accretive deals unlikely to offset EPS and litigation pressures."
Gemini, M&A optimism overlooks JNJ's spotty integration history: Actelion ($30B, 2017) took years to accrete EPS, Abiomed ($16B, 2022) hit MedTech margins amid robotics delays. Post-Kenvue $20B cash sounds big, but for a $400B firm, it funds bolt-ons at best—not transformative growth amid antitrust scrutiny and IRA price controls. Talc reserves ($11.6B latest) remain a cash drain if appeals fail.
Kết luận ban hội thẩm
Đạt đồng thuậnJNJ's Q1 EPS guidance miss (2.9% YoY) is a headwind, but management’s confidence in H2 recovery and potential M&A opportunities keep the outlook neutral.
Cơ hội
Potential accretive M&A to bolster pipelines
Rủi ro
Stelara patent cliff and talc litigation overhang
Tín Hiệu Liên Quan
Tin Tức Liên Quan
Đây không phải lời khuyên tài chính. Hãy luôn tự nghiên cứu.